Scilex Holding Company ( (SCLX) ) has issued an update.
Scilex Holding Company announced a significant move towards a business combination between its subsidiary, Semnur Pharmaceuticals, and Denali Capital Acquisition Corp. This merger aims to boost Semnur’s equity value to $2.5 billion, with plans to finalize by early 2025. Concurrently, Scilex is distributing preferred stock dividends to its shareholders, offering a unique opportunity for investors to capitalize on this strategic development. The merger promises to enhance growth prospects and diversify Scilex’s portfolio in the non-opioid pain management sector.
Find detailed analytics on SCLX stock on TipRanks’ Stock Analysis page.
Trending Articles
- All Eyes on Rivian Stock Ahead of Earnings Today — Here’s What Wall Street Expects
- Bentley Motors (NASDAQ:BSY) Pushes Back Its Own Green Goals
- Earnings Report Gives Canada Goose (TSE:GOOS) an Edge
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
